Motif Bio plc
Motif Bio plc (LSE: MTFB) is developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Motif has a lead antibiotic candidate, iclaprim, and MTF-001, a preclinical program to design a best-in-class dihydrofolate reductase inhibitor (DHFRi). Discussions and negotiations with academic institutions are under way to build a portfolio of antibiotic candidates through licensing. It is anticipated that Motif’s lead antibiotic candidate could be ready for commercialization as early as 2018.
Motif has recruited a highly experienced team of drug discovery scientists – former senior executives at Merck, Schering Plough, Wyeth, GlaxoSmithKline, and Bayer - in medicinal and computational chemistry, biology, toxicology, pharmacology, and clinical development to capitalize on the growing trend of pharmaceutical companies to outsource drug discovery to small specialized players.
Graham Lumsden- Chief Executive Officer
Robert Bertoldi- Chief Financial Officer, VP Business Development
David Huang M.D., Ph.D., JD- Chief Medical Officer
Matthew J. Wyvratt, Ph.D. - Senior Vice President, Drug Discovery
Jerauld S. Skotnicki, Ph.D. - Executive Director, Medicinal Chemistry
Mark L. Greenlee, Ph.D. - Executive Director, Medicinal Chemistry
Board of Directors
Richard C.E. Morgan - (Chairman) Chief Executive Officer, Amphion Innovations
Zaki Hosny- (Deputy Chairman)
Jon Gold - Senior Financial Analyst, Federated Investments
Dr. Mary Lake Polan - Board of Directors, Wyeth Corporation, formally Professor and Chair emeritus, Department of Obstetrics and Gynecology, Stanford University School of Medicine
Dr. John Stakes - Director of Specialty Care Development, Harvard Medical School and Massachusetts General Hospital
Bruce Williams - Biotechnology Industry Consultant, formally held senior marketing positions at Celgene Corp., and Ortho Biotech, a Johnson & Johnson company